rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The objective of this study was to determine whether ADRB1 Ser49Gly and Arg389Gly are associated with recovery of left ventricular ejection fraction (LVEF) in patients with heart failure.
|
30756358 |
2019 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The β1 adrenergic receptor (ADRB1) Arg389Gly, G-protein receptor kinase type 5 (GRK5) Gln41Leu, G-protein β-3 subunit (GNB3) 825 C/T, and α2c deletion affect adrenergic tone, impact heart failure outcomes and differ in prevalence by ethnicity.
|
30978507 |
2019 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism (ADRB1 Arg389Arg genotype).
|
29754666 |
2018 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We used uniform methodology to investigate BB dose-ADRB1 Arg389Gly polymorphism interaction with major clinical end points in BEST/bucindolol and HF-ACTION/other BB databases.
|
30354340 |
2018 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the β1 adrenergic receptor gene Arg389Gly polymorphism might not be associated with heart failure risk.
|
26125791 |
2015 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study sought to investigate whether ADRB1 Arg389Gly (rs1801253), GNAS -1211 G/A (rs6123837) and GNAS 2291 C/T (rs6026584) variants are associated with left ventricular function and exercise tolerance in heart failure patients.
|
23065660 |
2013 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We examined whether the Arg389Gly polymorphism in ADRβ1 interacts with the dose requirements of beta-blockers in patients with systolic HF.
|
23115322 |
2013 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Arg389Gly polymorphism has a major impact on the heart-rate response to carvedilol (but not bisoprolol) in patients with heart failure plus atrial fibrillation.
|
22617224 |
2012 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since the pivotal role of β1 adrenergic receptor (β1-AR) in HF, many publications have studied the associations between the β1-AR polymorphisms (Ser49Gly and Arg389Gly) and HF, with inconsistent results.
|
22815685 |
2012 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We investigated whether a predefined combination of the Arg389Gly polymorphism in the adrenergic β(1) -receptor gene (ADRB1) and the Gln27Glu polymorphism in the adrenergic β(2) -receptor gene (ADRB2) could predict survival in carvedilol- and metoprolol-treated chronic heart failure (HF) patients.
|
21395649 |
2011 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single nucleotide polymorphisms (SNPs) within the β(1)- (Ser49Gly, Arg389Gly) and β(2)-adrenoceptor (Arg16Gly, Gln27Glu, Thr164Ile) have been associated with alterations in adrenoceptor (AR) function sensitivity in vitro and in vivo and possibly contribute to HF progression.
|
20803192 |
2010 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One study of risk for heart failure suggested a synergistic effect of ADRB1 Arg389Gly with the insertion/deletion polymorphism in the alpha2C-adrenergic receptor gene (ADRA2C).
|
17496726 |
2007 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We tested the hypothesis that polymorphisms at codons 389 (Arg389Gly) and 49 (Ser49Gly) of the beta(1)-adrenergic receptor would be associated with differences in initial tolerability of beta-blocker therapy in patients with heart failure.
|
15735607 |
2005 |
rs1801253
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study.
|
12921807 |
2003 |